A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.-论文-万方医学网

作者： Yuanyuan,Wang ^[1] ; Tingxuan,Gu ^[2] ; Xueli,Tian ^[1] ; Wenwen,Li ^[2] ; Ran,Zhao ^[1] ; Wenqian,Yang ^[2] ; Quanli,Gao ^[2] ; Tiepeng,Li ^[1] ; Jung-Hyun,Shim ^[2] ; Chengjuan,Zhang ^[1] ; Kangdong,Liu ^[2] ; Mee-Hyun,Lee ^[3]

作者单位： Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. ^[1] China-US (Henan) Hormel Cancer Institute, Zhengzhou, China. ^[2] Department of Immunology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. ^[3] Department of Pharmacy, College of Pharmacy, Mokpo National University, Mokpo, South Korea. ^[4] Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. ^[5] College of Korean Medicine, DongShin University, Naju, South Korea. ^[6]

主题词动物(Animals);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);细胞系(Cell Line);细胞因子类(Cytokines);细胞毒性, 免疫(Cytotoxicity, Immunologic);疾病模型, 动物(Disease Models, Animal);剂量效应关系, 药物(Dose-Response Relationship, Drug);人类(Humans);肺肿瘤(Lung Neoplasms);淋巴细胞活化(Lymphocyte Activation);黑色素瘤(Melanoma);黑色素瘤, 实验性(Melanoma, Experimental);小鼠(Mice);模型, 生物学(Models, Biological);分子结构(Molecular Structure);蛋白质结合(Protein Binding);信号传导(Signal Transduction);构效关系(Structure-Activity Relationship);T淋巴细胞(T-Lymphocytes);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.3389/fimmu.2021.654463

PMID 34054817

发布时间 2021-09-29

检索历史清除

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

检索历史清除